HDx Opportunity Theranova's HDx platform targets a broader spectrum of molecules in kidney failure patients, addressing inflammation and cardiovascular risk. This positions Theranova to win contracts with nephrology clinics and dialysis networks seeking improved outcomes and potential cost savings through expanded dialysis capabilities.

Strategic Partnerships Opportunity to partner with large medical distributors and OEMs to accelerate market access. Strategic collaborations or white-label arrangements with industry players could scale field deployment beyond a lean 11-50 person team.

Clinical Advantage Clinical and payer readiness is critical. Invest in robust clinical performance data and payer economics to demonstrate improved patient outcomes and lower total costs of care, addressing reimbursement hurdles that often limit adoption.

Scale Readiness With current revenue in the low millions and a small workforce, Theranova can pursue licensing, investment, or manufacturing partnerships to expand production and field sales capacity to meet demand from larger hospital networks.

Global Expansion Leverage San Francisco base to pursue international pilots and regulatory pathways, unlocking dialysis markets overseas where HDx can address unmet needs and widen access to care.